[Biotech&Pharma] Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Browse By

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $23.00 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. The total gross proceeds from the offering, before deducting underwriters' discounts and commissions and estimated offering expenses, are $207 million.

Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint book-running managers and Nomura Securities International, Inc., H.C. Wainwright & Co. and Janney Montgomery Scott acted as co-managers for …

Full story available on Benzinga.com

Source Benzinga

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.